Penumbra Company Profile (NYSE:PEN)

About Penumbra (NYSE:PEN)

Penumbra logoPenumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment
  • Sub-Industry: N/A
  • Symbol: NYSE:PEN
  • CUSIP: N/A
  • Web: www.penumbrainc.com
Capitalization:
  • Market Cap: $3.22 billion
  • Outstanding Shares: 33,772,000
Average Prices:
  • 50 Day Moving Avg: $90.42
  • 200 Day Moving Avg: $86.37
  • 52 Week Range: $56.05 - $97.65
P/E:
  • Trailing P/E Ratio: 645.61
  • Foreward P/E Ratio: 954.50
  • P/E Growth: -70.28
Sales & Book Value:
  • Annual Revenue: $294.09 million
  • Price / Sales: 10.96
  • Book Value: $11.04 per share
  • Price / Book: 8.65
Profitability:
  • EBITDA: ($3,320,000.00)
  • Net Margins: -2.78%
  • Return on Equity: -2.58%
  • Return on Assets: -2.27%
Debt:
  • Current Ratio: 9.72%
  • Quick Ratio: 7.56%
Misc:
  • Average Volume: 145,472 shs.
  • Beta: 0.09
  • Short Ratio: 17.55
 

Frequently Asked Questions for Penumbra (NYSE:PEN)

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) posted its earnings results on Tuesday, August, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The firm had revenue of $80.60 million for the quarter, compared to analyst estimates of $77.16 million. Penumbra had a negative return on equity of 2.58% and a negative net margin of 2.78%. Penumbra's revenue was up 23.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.01 EPS. View Penumbra's Earnings History.

Where is Penumbra's stock going? Where will Penumbra's stock price be in 2017?

2 brokerages have issued 12 month target prices for Penumbra's stock. Their forecasts range from $96.00 to $100.00. On average, they expect Penumbra's stock price to reach $98.00 in the next twelve months. View Analyst Ratings for Penumbra.

Who are some of Penumbra's key competitors?

Who are Penumbra's key executives?

Penumbra's management team includes the folowing people:

  • Adam Elsesser, Chairman of the Board, President, Chief Executive Officer
  • Sridhar Kosaraju, Chief Financial Officer and Head of Strategy
  • Daniel Donen Davis, President, North America
  • James Pray, President, International
  • Robert D. Evans, Executive Vice President, General Counsel, Secretary
  • Lynn Rothman, Executive Vice President and Chief Business Officer
  • Arani Bose M.D., Executive Director and Chief Innovator
  • Harpreet S. Grewal, Independent Director
  • Don W. Kassing, Presiding Independent Director
  • Bridget O'Rourke, Independent Director

Who owns Penumbra stock?

Penumbra's stock is owned by a number of of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.28%) and Strs Ohio (0.05%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.

Who bought Penumbra stock? Who is buying Penumbra stock?

Penumbra's stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio and Nationwide Fund Advisors. View Insider Buying and Selling for Penumbra.

How do I buy Penumbra stock?

Shares of Penumbra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Penumbra's stock price today?

One share of Penumbra stock can currently be purchased for approximately $95.45.


MarketBeat Community Rating for Penumbra (NYSE PEN)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  170
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Penumbra (NYSE:PEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $98.00 (2.67% upside)
Consensus Price Target History for Penumbra (NYSE:PEN)
Price Target History for Penumbra (NYSE:PEN)
Analysts' Ratings History for Penumbra (NYSE:PEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017BMO Capital MarketsReiterated RatingBuy$96.00N/AView Rating Details
8/9/2017Canaccord GenuityReiterated RatingBuy$94.00 -> $100.00HighView Rating Details
3/14/2016Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Penumbra (NYSE:PEN)
Earnings by Quarter for Penumbra (NYSE:PEN)
Earnings History by Quarter for Penumbra (NYSE PEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.05)($0.05)$77.16 million$80.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.06)($0.10)$71.08 million$73.21 millionViewListenView Earnings Details
2/28/2017Q416($0.09)($0.08)$67.54 million$73.10 millionViewListenView Earnings Details
11/3/2016Q316($0.08)($0.04)$63.25 million$67.20 millionViewN/AView Earnings Details
8/9/2016Q216($0.07)$0.01$58.18 million$65.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.07)$0.02$53.10 million$57.90 millionViewN/AView Earnings Details
3/8/2016Q415($0.10)$0.05$46.76 million$54.40 millionViewN/AView Earnings Details
11/12/2015Q315($0.15)$0.03$43.00 million$50.42 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Penumbra (NYSE:PEN)
Current Year EPS Consensus Estimate: $-0.21 EPS
Next Year EPS Consensus Estimate: $0.10 EPS

Dividends

Dividend History for Penumbra (NYSE:PEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Penumbra (NYSE:PEN)
Insider Ownership Percentage: 13.50%
Institutional Ownership Percentage: 70.93%
Insider Trades by Quarter for Penumbra (NYSE:PEN)
Institutional Ownership by Quarter for Penumbra (NYSE:PEN)
Insider Trades by Quarter for Penumbra (NYSE:PEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Harpreet GrewalDirectorSell500$92.90$46,450.00View SEC Filing  
10/2/2017Thomas WilderDirectorSell345$90.20$31,119.00View SEC Filing  
9/29/2017Robert D EvansEVPSell20,017$90.03$1,802,130.51View SEC Filing  
9/28/2017Robert D EvansEVPSell2,108$90.00$189,720.00View SEC Filing  
9/27/2017Robert D EvansEVPSell1,586$90.00$142,740.00View SEC Filing  
9/21/2017Robert D EvansEVPSell4,983$90.00$448,470.00View SEC Filing  
9/20/2017Robert D EvansEVPSell2,859$90.00$257,310.00View SEC Filing  
8/21/2017Harpreet GrewalDirectorSell4,500$82.65$371,925.00View SEC Filing  
8/9/2017Robert D EvansEVPSell10,000$85.15$851,500.00View SEC Filing  
8/1/2017Daniel Donen DavisInsiderSell32,000$79.42$2,541,440.00View SEC Filing  
7/18/2017Thomas WilderDirectorSell345$86.10$29,704.50View SEC Filing  
4/24/2017Robert D EvansEVPSell10,000$85.24$852,400.00View SEC Filing  
2/14/2017Robert D EvansEVPSell5,000$75.00$375,000.00View SEC Filing  
2/13/2017Adam ElsesserCEOSell7,700$72.21$556,017.00View SEC Filing  
2/13/2017James Robert PrayInsiderSell1,700$73.04$124,168.00View SEC Filing  
2/13/2017Sridhar KosarajuCFOSell1,600$72.94$116,704.00View SEC Filing  
2/10/2017James Robert PrayInsiderSell23,900$71.08$1,698,812.00View SEC Filing  
2/10/2017Sridhar KosarajuCFOSell15,500$71.49$1,108,095.00View SEC Filing  
2/9/2017Arani BoseInsiderSell22,300$70.44$1,570,812.00View SEC Filing  
2/9/2017Lynn RothmanEVPSell2,700$70.20$189,540.00View SEC Filing  
2/7/2017James Robert PrayInsiderSell4,099$69.09$283,199.91View SEC Filing  
2/7/2017Robert D EvansEVPSell1$70.00$70.00View SEC Filing  
2/6/2017Arani BoseInsiderSell17,100$70.01$1,197,171.00View SEC Filing  
2/6/2017Lynn RothmanEVPSell2,886$70.41$203,203.26View SEC Filing  
2/6/2017Sridhar KosarajuCFOSell100$70.00$7,000.00View SEC Filing  
2/3/2017James Robert PrayInsiderSell15,600$70.39$1,098,084.00View SEC Filing  
2/3/2017Robert D EvansEVPSell5,000$70.35$351,750.00View SEC Filing  
2/3/2017Sridhar KosarajuCFOSell7,800$70.56$550,368.00View SEC Filing  
2/1/2017Adam ElsesserCEOSell21,400$70.98$1,518,972.00View SEC Filing  
2/1/2017Daniel Donen DavisInsiderSell7,298$71.00$518,158.00View SEC Filing  
2/1/2017Lynn RothmanEVPSell4,414$70.99$313,349.86View SEC Filing  
1/31/2017Adam ElsesserCEOSell9,000$71.26$641,340.00View SEC Filing  
1/31/2017Daniel Donen DavisInsiderSell3,000$71.29$213,870.00View SEC Filing  
1/31/2017Lynn RothmanEVPSell1,800$71.27$128,286.00View SEC Filing  
1/30/2017Adam ElsesserCEOSell8,200$70.72$579,904.00View SEC Filing  
1/30/2017Daniel Donen DavisInsiderSell2,698$70.71$190,775.58View SEC Filing  
1/30/2017Lynn RothmanEVPSell1,700$70.79$120,343.00View SEC Filing  
1/27/2017Arani BoseInsiderSell31,500$74.12$2,334,780.00View SEC Filing  
1/27/2017Lynn RothmanEVPSell7,000$74.24$519,680.00View SEC Filing  
1/26/2017Don W KassingDirectorSell3,000$74.50$223,500.00View SEC Filing  
11/16/2016Sridhar KosarajuCFOSell25,000$65.07$1,626,750.00View SEC Filing  
9/9/2016Adam ElsesserCEOSell57,200$71.07$4,065,204.00View SEC Filing  
9/6/2016Arani BoseInsiderSell61,000$70.72$4,313,920.00View SEC Filing  
9/2/2016Robert D EvansEVPSell3,100$70.10$217,310.00View SEC Filing  
8/31/2016Adam ElsesserCEOSell26,000$71.15$1,849,900.00View SEC Filing  
8/31/2016Robert D EvansEVPSell5,300$71.17$377,201.00View SEC Filing  
8/26/2016Adam ElsesserCEOSell26,800$71.06$1,904,408.00View SEC Filing  
8/26/2016Robert D EvansEVPSell5,300$71.03$376,459.00View SEC Filing  
8/24/2016Adam ElsesserCEOSell29,000$72.95$2,115,550.00View SEC Filing  
8/24/2016Robert D EvansEVPSell6,300$73.00$459,900.00View SEC Filing  
5/23/2016Robert D EvansEVPSell5,000$50.52$252,600.00View SEC Filing  
5/19/2016Don W KassingDirectorSell3,000$48.63$145,890.00View SEC Filing  
5/19/2016Robert D EvansEVPBuy1,538$25.50$39,219.00View SEC Filing  
5/16/2016James Robert PrayInsiderSell32,500$48.51$1,576,575.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Penumbra (NYSE:PEN)
Latest Headlines for Penumbra (NYSE:PEN)
Source:
Loading headlines, please wait.

Social

Chart

Penumbra (PEN) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.